Newsroom
Sorted by: Latest
-
Faraday Future Reminds Stockholders to Register for the Upcoming FF Stockholder Community & FX Developer Co-Creation Day on April 24
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (Nasdaq: FFAI) (“FF”, “Faraday Future”, or “Company”), a California-based global shared intelligent electric mobility ecosystem company, reminds stockholders and Developer Co-Creation candidates to register for its upcoming FF Stockholder Community & FX Developer Co-Creation Day on April 24, 2025. This exclusive event will unveil key updates and provide attendees with a firsthand look at the cutting-edge innovation, adva...
-
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced o...
-
REPLY S.p.A.: L’Assemblea degli Azionisti approva il Bilancio 2024
TORINO, Italia--(BUSINESS WIRE)--L’Assemblea degli Azionisti di Reply S.p.A. [EXM, STAR: REY] riunitasi in data odierna ha approvato il bilancio relativo all’esercizio 2024, confermando la distribuzione di un dividendo lordo pari a 1,15 Euro per azione. Il dividendo verrà posto in pagamento il 21 maggio 2025, con data di stacco dividendo fissata il 19 maggio 2025 (record date il 20 maggio 2025). Bilancio dell’esercizio 2024 Il Gruppo Reply ha chiuso l’esercizio 2024 con un fatturato consolidato...
-
REPLY S.p.A.: Shareholders’ Meeting Approves the 2024 Financial Statements
TURIN, Italy--(BUSINESS WIRE)--The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2024, confirming the distribution of a gross dividend of €1.15 per share. The dividend will be paid on 21 May 2025, with dividend date set on 19 May 2025 (record date on 20 May 2025). 2024 Financial Statement The Reply Group closed the 2024 financial year with a consolidated turnover of €2,295.9 million, recording a 8.4% increase compar...
-
REPLY S.p.A.: Die Hauptversammlung genehmigt den Jahresabschluss 2024
TURIN, Italien--(BUSINESS WIRE)--Die Hauptversammlung von Reply S.p.A. [EXM, STAR: REY], die heute zusammengekommen ist, hat den Jahresabschluss für das Jahr 2024 gebilligt und die Ausschüttung einer Brutto-Dividende von 1,15 Euro je Aktie genehmigt. Die Dividende wird am 21. Mai 2025 ausgezahlt, wobei das Ex-Datum mit 19. Mai 2025 und der Stichtag (record date) mit 20. Mai 2025 festgesetzt sind. Ergebnisse des Geschäftsjahres 2024 Die Reply-Gruppe beendete das Geschäftsjahr 2024 mit einem Konz...
-
Southwest Wisconsin Technical College and Ameresco Celebrate Completion of Solar and Battery Storage Project
--(BUSINESS WIRE)--WHAT: Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition, and Southwest Wisconsin Technical College invite media to attend a ribbon-cutting ceremony celebrating the completion of a new solar array and battery energy storage system (BESS) on campus. The $1.6 million project includes a 300-kilowatt solar array, and a 125-kilowatt BESS designed to offset approximately 60% of the electricity used in Buil...
-
Aurion Biotech Appoints Edward J. Holland, M.D., as Chief Medical Officer and Eris P. Jordan, O.D., as Chief Development Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, a clinical-stage regenerative medicine company whose mission is to restore vision to millions of patients, today announced the appointments of Edward J. Holland, M.D., as Chief Medical Officer, and Eris P. Jordan, O.D., as Chief Development Officer. Aurion Biotech is developing AURN001, an investigational, single-administration, allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial disease...
-
Summit Bank Group Reports 2025 1st Quarter Earnings
EUGENE, Ore.--(BUSINESS WIRE)--Summit Bank Group (OTC Pink: SBKO) Q1 2025 Net Income of $2.93 million or $0.37 per fully diluted share; an increase of 20.2 percent over Q1 2024. Q1 2025 Net Income increased from $2.42 million or $0.31 per share for Q1 2024. Cash and Securities total $189.5 million – 14.8 percent of assets. Year over year Net Loan Growth - $93.4 million or 9.6 percent over March 31, 2024. Year over year Deposit Growth - $118.1 million or 11.6 percent over March 31, 2024. Q1 2025...
-
Desired Effect Launches First Vuln/Exploit Ethical Market - Brings Defenders to the Pre-Attack Buying Pool, Strips Attackers of Cheap Exploits and First-Mover Edge
SAN FRANCISCO & BALTIMORE--(BUSINESS WIRE)--Marketplace for Zero Day exploit data enables ethical exchange of exploits, lets defenders act before an attack & ends attackers' 1st mover advantages...
-
Thermo Fisher Scientific Reports First Quarter 2025 Results
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and t...